Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report

Tadashi Yokoyama, Hiroshi Makino, Atsushi Hirakata, Junji Ueda, Hideyuki Takata, Mikihiro Okusa, Manpei Kawashima, Takeshi Tsujino, Masaru Hosone, Akira Matsushita, Yoshiharu Nakamura and Hiroshi Yoshida

We report a case of metastatic pancreatic-head mucinous carcinoma (with multiple lymph node and bone metastases) and review the relevant literature. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) was useful for diagnosis, and a satisfactory outcome was achieved by using systemic chemotherapy with FOLFIRINOX followed by resection of the primary lesion as conversion surgery. The patient was a 55-year-old man. Hematological findings included elevated serum tumor marker levels: CEA 12.7 ng/mL, DUPAN-2 400 U/mL. Findings from several imaging modalities and EUS-FNA confirmed a clinicopathological diagnosis of metastatic pancreatic mucinous carcinoma with multiple bone and lymph node metastases. Five courses of modified FOIFIRINOX (m-FFX) were given as systemic chemotherapy, which had an antitumor effect. Subtotal stomach-preserving pancreaticoduodenectomy and extensive lymph-node dissection were thus performed. Histopathological analysis showed invasive ductal carcinoma, muc (pT3, pN1b, cM1). After surgery, the clinical course was notable for the absence of complications. Tegafur/gimeracil/oteracil (S-1) was started as maintenance adjuvant chemotherapy postoperatively, and no disease progression has been observed at 10 months after surgery.

(J Nippon Med Sch 2019; 86: 284–290)

Key words: pancreatic mucinous carcinoma, modified FOLFIRINOX, conversion surgery

Introduction
We report a case of metastatic pancreatic-head mucinous carcinoma (with multiple lymph node and bone metastases) and review the literature. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) was useful for diagnosis, and a satisfactory outcome was achieved by using systemic chemotherapy with modified FOLFIRINOX followed by resection of the primary lesion as conversion surgery.

Case
A 55-year-old man with abdominal distention and low back pain visited a local gastroenterologist in 2017. A 5-cm hypoechoic tumorous lesion was detected in the pancreatic head region via abdominal ultrasound examination, and the patient was referred to our hospital for further examination and treatment.

Hematological findings: No bone marrow suppression was detected.

Biochemical findings showed slight elevations: LDH 588 IU/L, ALP 495 IU/L, and AMY 228 IU/L. There were elevated serum tumor marker levels of CEA 12.7 ng/mL and DUPAN-2 400 U/mL, but CA 19-9 was within the normal range, at 20.8 U/mL. There was no evidence of
diabetes.

Abdominal CT image: A heterogeneous clearly demarcated 50-mm tumorous lesion was detected in the head of the pancreas. The main pancreatic duct was dilated in the tail of the pancreas because of retraction associated with the lesion. Lymph node enlargement was observed as an extensive mass involving the pancreatic head region and the upper mesenteric and bilateral para-aortic regions (Fig. 1a and b).

MRCP detected a mass of 52 × 50 × 100 mm involving the head of the pancreas. Mild distention due to retraction was observed in the peripheral main pancreatic duct, although there was no continuity with the tumor (Fig. 1c).

PET-CT: FDG accumulation was observed in the pancreatic head tumor, mesenteric lymph nodes, and lymph nodes in the para-aortic regions, as well as in the left scapula, vertebral column, sternum, pelvic bone, and bilateral ribs as multiple bone findings (Fig. 2).

EUS-FNA: An oval hypoechoic tumorous lesion (51 × 40 mm), with posterior echo enhancement, was detected in the head of the pancreas and formed a mass with adjacent lymph nodes. The tumor was enclosed in a capsule, and the internal echo revealed a mixture of solid and microcystic aggregate-like components—a so-called “sponge-like” structure (Fig. 3a and b). Aspiration cytology and biopsy were performed (Fig. 3c).

After definitive histological diagnosis of mucinous carcinoma (Fig. 4), the patient received a clinicopathological diagnosis of metastatic pancreatic head mucinous carcinoma with multiple bone and lymph node metastases. The choices for systemic chemotherapy included FOLFIRINOX\(^1\) and combination therapy with gemcitabine and nab-paclitaxel (GEMNAB)\(^2,3\); we chose FOLFIRINOX as the primary chemotherapeutic regimen.

Regimen Management

In accordance with the hematological and non-hematological toxicity grading scales for Japanese\(^4\), a total of five courses of modified FOLFIRINOX (m-FFX: 5-
fluorouracil 2,400 mg/m² on 46-h infusion, leucovorin 400 mg/m² div, irinotecan 150 mg/m² div, oxaliplatin 85 mg/m² div) was administered every 2 weeks⁵, along with zoledronic acid 4 mg/day, every 4 weeks, to assist in treating bone metastases. Hematological adverse events included neutropenia, anemia, and thrombocytopenia (grade 1), and non-hematological toxicities included general malaise and loss of appetite (maximum, grade 2), as evaluated by NCI-CTC version 2.0 scores. The treatment was well-tolerated in this patient.

As for treatment outcome, contrast-enhanced CT and PET-CT images obtained at completion of five courses showed decreases in the size of the primary (32 × 25 mm) and lymph node metastatic lesions, as evaluated by RECIST criteria, and in the amounts of FDG aggregates (clinical partial response: cPR). Moreover, treatment of bone metastases achieved a clinical complete response (cCR), as no FDG uptake was seen on PET-CT (Fig. 5).

Serum levels of LDH, ALP, CEA, and DUPAN-2 were lower (183 IU/L, 315 IU/L, 3.8 ng/mL, and 240 U/mL, respectively) than baseline levels at the first visit.

Clinical Course
The expansive growth pattern of the tumor, including the lymph node metastatic lesions, suggested that wide resection of the tumor including the primary lesion might yield excellent short-term and good long-term outcomes. The patient was therefore scheduled for surgery after completion of the five courses of m-FFX. Subtotal stomach-preserving pancreaticoduodenectomy and extensive lymph node dissection were performed.

The operation time was 508 minutes, and the amount of blood loss was 308 mL. The resected specimen showed a tumor 38 × 30 mm in diameter in the head of the pancreas. Colloidal mucus was observed inside the tumor, and yellowish-white solid components were detected on
Surgery for metastatic pancreatic mucinous carcinoma

Fig. 3  EUS
a: The pancreatic head tumor (51 × 40 mm) enclosed in a capsule; internal echo revealing a mixture of solid and microcystic aggregate-like components.
b: Metastasis to adjacent lymph nodes.
c: EUS-FNA.

Fig. 4  Pathological results of EUS-FNA: diagnosis of mucinous carcinoma.
a, b: Tumor cells stained with Papanicolaou stain (a: ×20, b: ×100).
c, d: Biopsy tissue stained with hematoxylin-eosin (c: ×100, b: ×400).
Fig. 5  CT and PET-CT (after completion of five courses of m-FFX)

a: CT imaging revealing reductions in the size of the primary tumor and multiple lymph node metastases (cPR).
b, c: Amount of FDG aggregates was reduced in the pancreatic tumor and multi-region lymph nodes.
d: Bone metastases: absence of FDG uptake indicates cCR.

Discussion

According to the Japanese “General Rules for the Study of Pancreatic Cancer, 7th edition”, pancreatic mucinous carcinoma is a type of invasive ductal carcinoma and is rare (about 1.3% of pancreatic epithelial tumor cases in Japan). Pathological characteristics of this carcinoma include marked mucus production (leading to formation of mucous lakes), fibrotic changes around individual mucous lakes and the entire tumor lesion, and cancer cells with various degrees of differentiation on the margins and inside the mucinous lakes. According to these guidelines, mucinous cancer is diagnosed if more than
Surgery for metastatic pancreatic mucinous carcinoma

Fig. 6 Histopathological findings.

a, b: Macroscopic views: 50 × 32 mm tumor (head of the pancreas).

c, d: Microscopic views: formation of mucous lakes with abundant mucus production and existence of a very small number of free-floating cancer cells inside the mucus.

80% of the entire tumor lesion is occupied by mucinous lakes.

Tumor metastasis was observed in the present patient. Therefore, systemic chemotherapy was selected as the treatment regimen, and FOLFIRINOX and GEMNAB were considered as first-line therapies. On the basis of previous reports on other mucus-producing cancers, we selected FOLFIRINOX, a regimen containing a platinum-based agent (oxaliplatin). After completion of five courses of this regimen, a clinical complete response (cCR) was achieved for bone metastases, and a partial response was achieved for the primary lesion and lymph node metastases. This satisfactory clinical course enabled conversion surgery. Our results indicate that this treatment regimen was appropriate.

It is unclear if conversion surgery is indicated for metastatic pancreatic carcinoma. Several previous studies reported that the rate of conversion surgery for unresectable pancreatic carcinoma after FORFIRINOX was 20% to 50%, but the quality of evidence was low. As of 2018, numerous studies have reported that tumor resection after systemic chemotherapy-so-called neoadjuvant chemotherapy (NAC)—can increase time to recurrence and survival time, as compared with provisional surgery, in cases of locally advanced pancreatic carcinoma. The quality of evidence for this strategy is high, when studies from all countries are considered. Nevertheless, concerns remain regarding conversion surgery for unresectable pancreatic carcinomas, including those classified as stage IVb.

The present adjuvant chemotherapy regimen was similar to those selected for ordinary pancreatic carcinomas. The “Clinical Guidelines for the Management of Pancreatic Cancer” issued by the Japan Pancreas Society, recommends that S-1 be given for 6 months, as reported by Usaka et al. It is not known if pyrimidine fluoride agents are effective for treatment of mucinous carcinoma, as in the present case; nevertheless, we chose S-1 for our patient, because of concerns regarding tolerability. Because pancreatic carcinoma is rare histologically, evidence regarding optimal treatment is insufficient.

No previous study has reported conversion surgery for metastatic pancreatic mucinous carcinoma. Therefore, our patient is being followed carefully, to identify any prognostic differences from usual invasive ductal carcinoma.

In conclusion, conversion surgery is possible for patients with metastatic pancreatic carcinoma but depends on the clinical course of systemic multidisciplinary therapy.
Conflict of Interest: None.

References
1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissi-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducrueux M, for the Groupe Tumeurs Digestives of Uncancer and the PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
2. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Taberner J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
3. Kunzmann V, Herrmann K, Bluemel C, Kapp M, Hartlapp I, Steger U: Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer. Case Rep Oncol 2014; 7: 648–655.
4. Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H, Boku N: Phase II study of FOLFIRINOX for chemotheraoy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci 2014; 105: 1321–1326.
5. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T: Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 2015; 22: 1153–1159.
6. Mahaseth H, Bruther C, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Maithel SK, Landry J, El-Rayes BF: Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013; 42: 1311–1315.
7. Fukushima N, Mukai K, Kanai Y, Hasebe T, Shimada K, Ozaki H, Kinoshita T, Koyuga T: Intraductal papillary tumors and mucinous cystic tumors of the pancreas: clinicopathologic study of 38 cases. Hum Pathol 1997; 28: 1010–1017.
8. Iacobuzio-Donahue CA, Wilentz RE, Argani P, Yeo CJ, Cameron JL, Kern SE, Hruban RH: Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000; 24: 1544–1548.
9. Liszka L, Zielinska-Pajak E, Pajak J, Golka D: Colloid carcinoma of the pancreas: review of selected pathological and clinical aspects. Pathology 2008; 40: 655–663.
10. Luttges J, Zamboni G, Longnecker D, Kloppel G: The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 2001; 25: 942–948.
11. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004; 28: 219–230.
12. Thompson LD, Becker RC, Przygodzki RM, Adair CF, Heffess CS: Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg Pathol 1999; 23: 1–16.
13. Whang EE, Danial T, Dunr JC, Ashley SW, Reber HA, Lewin TJ, Tompkins RK: The spectrum of mucin-producing adenocarcinoma of the pancreas. Pancreas 2000; 21: 147–151.
14. Yamada M, Kozuka S, Yamao K, Nakazawa S, Naitoh Y, Tsukamoto Y: Mucin-producing tumor of the pancreas. Cancer 1991; 68: 159–168.
15. Zhai J, Sarkar R, Ylagan L: Pancreatic mucinous lesions: a retrospective analysis with cytohistochemical correlation. Diagn Cytopathol 2006; 34: 724–730.
16. Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Damnrich D, Hurtado-Cordova J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchant JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ: Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology 2015; 15: 667–673.
17. Antonios A, Charios J, Tohme C: Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care? Future Oncol 2017; 13: 951–953.
18. Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G: Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer 2016; 16: 786.
19. Hackert T, Sachsenhaer M, Hinz U, Schneider L, Michalski CW, Springfield C, Strobel O, Jager D, Ulrich A, Buchler MW: Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg 2016; 264: 457–463.
20. Okada K, Kawai M, Hirono S, Sato S, Yanagimoto H, Ioka T, Miyazawa M, Shimizu A, Kitahata Y, Yamaue H: Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol 2016; 78: 719–726.
21. Usaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y, for the JASPAC 01 Study Group: Neoadjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248–257.

(Received, October 20, 2018)
(Accepted, April 9, 2019)
(J-STAGE Advance Publication, May 17, 2019)